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Abstract
UDP-Glucose 6-dehydrogenase (UGDH) produces UDP-α-D-glucuronic acid, the precursors for 
glycosaminoglycans (GAGs) and proteoglycans (PGs) of the extracellular matrix. Elevated GAG 
formation has been implicated in a variety of human diseases, including glioblastoma (GBM). In 
our previous study, we found that krÜppel-like factor 4 (KLF4) promotes GBM cell migration by 
binding to methylated DNA, mainly methylated CpGs (mCpG) and transactivating gene 
expression. We identified UDGH as one of the downstream targets of KLF4-mCpG binding 
activity. In this study, we show that KLF4 upregulates UGDH expression in a mCpG-dependent 
manner, and UGDH is required for KLF4 induced cell migration in vitro. UGDH knockdown 
decreases glycosaminoglycan (GAG) abundance in GBM cells, as well as cell proliferation and 
migration in vitro. In intracranial xenografts, reduced UGDH inhibits tumor growth and migration, 
accompanied by a decrease in the expression of extracellular matrix proteins such as tenascin C, 
brevican. Our studies demonstrate a novel DNA methylation-dependent UGDH upregulation by 
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KLF4. Developing UGDH antagonists to decrease the synthesis of extracellular matrix 
components will be a useful strategy for GBM therapy.
Introduction
Glioblastoma (GBM, Grade IV glioma) is one of the most devastating forms of cancer and 
characterized by highly proliferative tumor growth and intensive tumor cell infiltration into 
normal brain tissues.1,2 An increased understanding of the molecular mechanisms 
underlying the aggressive behavior of tumor cells and the microenvironment in which they 
invade could provide insights into novel treatment strategies for this deadly disease. The 
extracellular matrix (ECM) is one of the critical components of the tumor microenvironment 
and provides essential biochemical and mechanical cues that direct cell growth, survival, 
migration and differentiation.3,4 Cell adhesion to the ECM permits growth factor-dependent 
activation of oncogenic signals, which promotes cell cycle progression and cell proliferation, 
while also functioning as either a barrier or a movement track to inhibit or promote cell 
migration.5 The ECM is mainly composed of fibrous proteins (e.g., collagen) and gel-like 
substance, such as glycosaminoglycans (GAGs), which are long polysaccharide chains with 
negative charges that attract water and soluble molecules including growth factors.6
GAGs are synthesized by an enzyme called UDP-glucose 6-dehydrogenase (UGDH). In our 
prior work, we found that krÜppel-like factor 4 (KLF4) binds to methylated CpGs (mCpG) 
in cis-regulatory elements, and activates gene expression, including UGDH, in GBM cells to 
exert phenotypic changes such as increased cell migration.7 DNA methylation at cis-
regulatory regions, mostly occurring at the CpG dinucleotide sites, is linked to gene 
repression and more recently gene activation.7,8 Given the importance of extracellular matrix 
function, specifically GAGs, in GBM; and the fact that UGDH is implicated as a rate-
limiting and essential step in GAG monosaccharide synthesis.9–11 the mCpG-dependent 
activation of UGDH prompts us to investigate the biological function of UGDH in GBM.
GAG formation is part of glucose metabolism: glucose is converted to glucose-1-phosphate 
then to UDP-glucose (UDP-Glu), an active form of glucose, which is further converted to 
UDP-glucuronic acid (UDP-GlcA). UDP-GlcA is the indispensable precursor for the 
synthesis of GAGs. The enzyme UDP-glucose 6-dehydrogenase (UGDH) catalyzes the 
biosynthetic oxidation of UDP-glucose to UDP-glucuronic acid,9,11 which are the building 
blocks of GAGs including hyaluronic acid and proteoglycans such as brevican, versican, 
aggregan etc. GAG synthesis pathways and key players are shown in (Figure 1).
GAGs reside in the extracellular space providing structural support for cells, as well as 
promoting cell adhesion, motility, angiogenesis and wound healing.12,13 Elevated GAG 
formation is implicated in a variety of human diseases, including the progression of 
epithelium tumors, breast cancers and brain tumors.6,14 Although GAGs are shown to be 
implicated in tumor progression, decrease in the synthesis of GAG precursor UDP-
glucuronic acid in GBM biology has not been investigated. In this current work, we 
investigated the methylation-dependent regulation of UGDH, as well as the biological 
function of UGDH in GBM cells. These findings identify UGDH as a potential therapeutic 
target for GBMs.
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Reagents and Cell Cultures
All reagents were purchased from Sigma-Aldrich unless otherwise stated. Doxycline (Dox) 
was diluted to a concentration of 1μg/ml in cell culture medium as a working concentration. 
The human glioblastoma (GBM) cell lines U87 were originally purchased from ATCC 
(Manassas, VA). GBM neurosphere culture (HSR-GBM1A) were originally established by 
Vescovi and colleagues15 and further characterized by us.16–18 Both cells lines are free from 
mycoplasma and authenticated with short tandem repeat (STR) profiling by Johns Hopkins 
Genetic Resources Core facility using Promega GenePrint 10 system (Madison, WI). U87 
cells were cultured in Minimum Essential Media (MEM, Thermo Fisher Scientific, Grand 
Island, NY) supplemented with sodium pyruvate (1%), sodium bicarbonate (2%), non-
essential amino acid (1%) and 10% fetal calf serum (FCS, Gemini Bio-products, West 
Sacramento, CA). HSR-GBM1A (GBM1A) cells contain CD133+ GBM stem-like cells and 
form infiltrative orthotropic xenografts that have been extensively characterized by others 
and our group.19,20 GBM1A neurospheres were cultured in DMEM/F12 medium 
supplemented with epidermal growth factor (EGF) (Peprotech, Rocky Hill, NJ) and 
fibroblast growth factor (FGF) (Peprotech). Cells were incubated in a humidified incubator 
containing 5% CO2/95% air at 37°C, and passaged every 4-5 days.
Lentiviral Transduction
UGDH shRNA lentiviral particles were purchased from Dharmacon (Buckinghamshire, 
UK). Control (non-silencing) shRNA clone ID RHS4348, UGDH sh#1 clone ID 
V2LHS-171838 and UGDH sh#2 clone ID V3LHS-412961. GBM cells were transduced 
with virus for 48 hrs prior to puromycin selection (1 μg/ml) as previously described.21 
Control cells were transduced with non-silencing control shRNA.
Quantitative real-time PCR
Total RNA was extracted using RNeasy Mini Kit (Qiagen, Mansfield, MA). After reverse 
transcription using MuLV reverse transcriptase (Applied Biosystems, Calsbad, CA) and 
Oligo(dT) primer, quantitative real-time PCR (qRT-PCR) was performed using SYBR Green 
PCR Mix (Applied Biosystems) and IQ5 detection system (Bio-Rad, Hercules, CA). Primer 
sequences are listed in Supplementary Table 1. Relative gene expression was normalized to 
18S rRNA.
Immunoblot and Immunocytochemistry
Total cellular protein was extracted with radioimmunoprecipitation assay (RIPA) buffer 
containing protease and phosphatase inhibitors (Millipore, Billerica, MA) and sonicated for 
15 seconds; the suspensions were centrifuged at 3,000 g for 10 minutes. SDS-PAGE was 
performed with 30-60 μg total proteins using 4% to 12% gradient Tris-glycine gels (LI-COR 
Biosciences, Lincoln, NE). Western blot analysis was performed using the Quantitative 
Western Blot System, with secondary antibodies labeled by IRDye infrared dyes (LI-COR 
Biosciences). Antibodies were purchased from: anti-KLF4 (Santa-Cruz, Dallas, TA); anti-
UGDH, anti- RABGEF1, anti-NGEF, anti-Brevican (Abcam, San Francisco, CA); anti- 
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PHLDB2 (Bethyl Labs, Montgomery, TX); anti-tenascin C (Millipore), anti- phospho-AKT, 
anti-total AKT, anti-cyclin B1, E1 and D1 (Cell signaling, Danvers, MA) and anti-β-actin.
For staining, GBM cells grown on chamber slides were fixed with 4% paraformaldehyde for 
30 min at 4°C and permeabilized with PBS containing 0.1% Triton X-100 for 10 min. The 
cells were then incubated with primary antibodies at 4°C overnight and then incubated with 
appropriate corresponding secondary antibodies conjugated with alexa fluorescent 488 or 
cy3 for 1hr at room temperature. Slides were mounted with vectashield antifade solution 
containing DAPI (Vector Laboratories, Burlingame, CA) and observed under fluorescent 
microscopy. Immunofluorescent images were taken and analyzed using Axiovision software 
(Zeiss, Germany).
Chromatin immunoprecipitation (ChIP)-PCR
A commercial ChIP-grade anti-KLF4 antibody (H180; Santa Cruz) recognizing the N-
terminal region of KLF4 was used for ChIP (DNA-binding domains of KLF4 are located to 
the C-terminus). Tet-on KLF4 WT and R458A GBM cells were treated with Dox for 48 hr 
followed by ChIP using the anti-KLF4 antibody and Dynabeads Protein A/G (Thermo Fisher 
Scientific) according to a protocol described previously.7,8 Primers targeting KLF4 binding 
sites were identified from previous ChIP-Seq analysis7 Primers targeting promoter regions 
lacking KLF4 binding sites were used as a negative control.
Assessment of CpG methylation status by bisulfite sequencing
Sanger bisulfite sequencing was performed as previously described.8 Purified genomic DNA 
from GBM cells were treated by EZ DNA Methylation-Direct Kit (Zymo Research, Irvine, 
CA). After bisulfite conversion, regions of interest were PCR-amplified using Taq 
polemerase. The primers used for bisulfite sequencing are listed in Supplemental Table 2. 
PCR products were cleaned up and cloned into a TA vector (Thermo Fisher Scientific). 
Individual clones were sequenced (Genewiz, Cambridge, MA) and aligned with the 
reference sequence.
Quantitative measurement of glycosaminoglycans (GAG)
The quantity of GAG was determined using the 1,9 dimethyl-methylene blue (DMMB) 
binding method with modifications as described by Barbosa et al.22 Briefly, the cells were 
digested with 0.2% papain in reaction buffer consisting of 0.1 M NaH2PO4, 5 mM Na2-
EDTA, and 5 mM cysteine–HCl pH 6.0, at 60 °C for 6 h. Total cell lysates were 
concentrated and adjusted to a concentration of 0.1 mg protein in 50 μl before mixing with 
200 μl of DMMB solution (40 mM glycine, 40 mM NaCl, 9.5 mM HCl, and 0.0016% 
DMMB, pH 3.0) in each well of a 96-well microtiter plate. The absorbance was immediately 
recorded at 525 nm using a plate reader (Perkin Elmer, Waltham, MA). Serial dilutions of 
shark chondroitin-6-sulphate, ranging from 5 to 25 μg/ml, were used to establish a standard 
curve, and duplicate wells with 50 μl of papain digestion buffer were used as blanks. Sample 
concentrations were calculated using linear regression of the standard curves.
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Cell migration assays were performed using transwell chambers as we previously described.
21,23
 The upper chamber medium consisted of either neurosphere cell culture medium 
without EGF/FGF or U87 cell media without FBS, and the lower chamber medium consisted 
of DMEM with 10% FBS. After 4-24 hours, cells that had migrated through the filter were 
fixed with Diff-Quick kit (Thermo Fisher Scientific). Cells on the upper side of the 
transwells were gently wiped off with Q-tips. Cells migrating through the filter were stained 
with 4′-6-Diamidino-2-phenylindole (DAPI). Migration was quantified by counting cells on 
five randomly selected fields per transwell in at least three independent experiments.23
Scratch Assay
GBM cells were grown under 10% FCS medium in 35 mm dishes until confluent. Several 
scratches were created using a 10 μl pipette tip through the confluent cells. Dishes were 
washed with PBS for 3 times and cells were grown in 0.1% FCS medium for 24-48 hr. Phase 
contrast pictures were taken at different time points. The width of the scratch was measured 
and areas of wound healing were measured and quantified using ImageJ.
Neurosphere formation assays
Viable cells (2 × 103/well or 2 × 104/well) were cultured in 48-well or 6-well plates, 
respectively. After 7-14 days, neurospheres were fixed in medium with 1% agarose, stained 
with 1% Wright stain solution and counted by computer-assisted morphometry (MCID 
software, Cambridge, UK) by measuring the number of neurospheres (>50 μm or >100 μm 
in diameter, as indicated) in three random fields per well.
Colony formation Assay
Anchorage-independent tumor cell proliferation was assessed by colony formation in soft 
agar. UGDH knockdown U87 cells or control-transduced cells were plated 10,000 cells per 
well in 0.5% agarose medium on top of regular medium containing 1% agarose and 
incubated for 2 weeks. The cells were stained blue with 1% Wright stain solution, and the 
number of colonies larger than 100 μm in diameter was determined by computer-assisted 
image analysis MCID.
Cell Cycle Analysis
Cell cycle was analyzed by flow cytometry on a FACSCalibur (Becton-Dickinson, Mountain 
View, CA).24 After plating in normal medium overnight, U87 cells were synchronized by 
changing into 0.1% FCS medium for 48 hrs followed by stimulation with 10% FCS for the 
indicated time points. To harvest, cells were trypsinized and dissociated by pipetting, fixed 
with 75% ethanol at 4 °C for 30 min. Cells were then incubated with DNase-free RNase at 
37 °C for 30 min followed by propidium iodide (100 ng/ml) for 1 h at 37 °C. The percentage 
of cells at each cell-cycle phase (G1/G0, S and G2/M) was analyzed using CellQuest 
software (Becton-Dickinson).
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All animal protocols were approved by the Johns Hopkins School of Medicine Animal Care 
and Use Committee. Each 6-8 week old female BALB/c strain immunodeficient (SCID) 
mouse received 10,000 viable neurosphere cells in 2 μL PBS by stereotactic injection to the 
right caudate/putamen (AP = 0 mm, ML = −2.5 mm, DV = −3.0 mm). After 7 weeks, mice 
were sacrificed and perfused with 4% paraformaldehyde; the brains were removed for 
histological analysis. Tumor sizes were quantified by measuring maximum tumor volume on 
hematoxylin and eosin–stained brain coronal sections using computer-assisted morphometry 
(MCID software) and then applying the formula Volume = (square root of maximum cross-
sectional area).3,20 The primary antibodies used for immunofluorescent staining are the 
following: monoclonal anti-Ki67 (BD Biosciences, Franklin Lakes, NJ), anti-TNC 
(Millipore), anti-Brevican (Abcam), and anti-laminin (Millipore).
To observe tumor cell migration in vivo, we mixed one portion of red fluorescent protein 
(RFP)-labeled control non-silencing cells (50,000) with three portion of green fluorescent 
protein (GFP)-labeled UGDH knockdown cells (150,000), and injected the mixture into the 
same mouse brains (n=3). Animals were sacrificed after 4 weeks and brain sections were 
observed under fluorescence microscopy.
Large scale data analysis, statistical analysis
All the raw data for our large-scale RNA-sequencing and KLF4 chromatin 
immunoprecipitation-sequencing (ChIP-seq) have been deposited in GEO (GSE97632). The 
link is: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
token=wjydoqaqxzgnxwz&acc=GSE97632. The methods to generate this data have been 
described in Wan et al in details.7
Statistical analysis was performed using Prizm software (GraphPad, La Jolla, CA, 
www.graphpad.com). Post hoc tests included the Students T-test and Tukey multiple 
comparison tests as appropriate. All in vitro experiments reported here represent at least 
three independent replications. All data are represented as mean value ± standard error of 
mean (S.E.); significance was set at P < 0.05.
Results
KLF4-mCpG interactions activate genes involved in migration
In our previous studies, we firmly established that KLF4 could activate transcription of >100 
genes via a non-canonical binding activity to methylated CpG (mCpG) to promote GBM cell 
migration.7 We observed that one third of such genes are involved in cytoskeletal 
organization, extracellular matrix formation and cell migration (Supplemental Fig. 1). To 
further interrogate the biological function of KLF4-mCpG binding activity, two previously 
characterized tet-on inducible human glioblastoma (GBM) U87 cell lines were used: one 
expressing KLF4 wild type (KLF4 WT) and the other KLF4 site-specific mutant (KLF4 
R458A), which lacks the mCpG-dependent binding activity but retains KLF4 canonical 
binding activity.7 Real-time PCR (RT-PCR) and ChIP-PCR were utilized to examine the 
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expression of selected KLF4 downstream target genes in GBM cells. Genes activated by 
KLF4 WT but not by KLF4 R458A would be recognized as a putative KLF4-mCpG target.
We selected the top 20 genes significantly upregulated by KLF4 WT, and associated with 
migration and cytoskeletal reorganization from our RNA-seq and gene ontology data,7 
respectively. Gene expression was quantified in tet-on inducible U87 KLF4 WT cells +/− 
Dox, and tet-on inducible U87 KLF4 R458A cells +/− Dox (Figure 2A). Our results 
demonstrated that KLF4 WT and KLF4 R458A differently induced gene expression. 
Specifically, eleven of the twenty genes, such as neuronal guanine nucleotide exchange 
factor (NGEF), pleckstrin homology like domain family B member 2 (PHLDB2), RAB 
guanine nucleotide exchange factor (GEF) 1 (RABGEF1), and UDP-α-D-glucose 6-
dehydrogenase (UGDH), were highly induced by KLF4 WT, but not by KLF4 R458A at the 
mRNA level (Figure 2A, asterisks), indicating that activation of these genes was dependent 
on mCpG-dependent binding of KLF4. To further confirm that the gene activation occurred 
via KLF4 binding to mCpGs in cis-regulatory regions, we performed bisulfite sequencing to 
examine the methylation status of the KLF4-binding regions of these genes based on our 
previous ChIP-seq data.7 We found that nine of the eleven KLF4 WT-upregulated genes 
were associated with highly methylated regions (Figure 2A, bold), and some examples are 
shown in Figure 2B.
We next performed ChIP-PCR to examine binding activity of KLF4 WT and KLF4 R458A 
to the cis-regulatory regions of a subset of the nine genes, including PHLDB2, RABGEF1, 
NGEF and UGDH. An anti-KLF4 antibody that recognizes both KLF4 WT and KLF4 
R458A was used to ChIP the chromatins in KLF4 WT and KLF4 R458A expressing cells 
48-hrs post Dox induction.7 The resulting ChIP-PCR data demonstrated that KLF4 WT 
preferentially bound to the cis-regulatory regions of these upregulated genes, whereas KLF4 
R458A showed much weaker or no binding signals to the same region (Figure 2C). In 
addition, KLF4 WT increased protein expression of PHLDB2, RABGEF1, and UGDH in 
comparison to KLF4 R458A (Figure 2D), corroborating that these genes could be functional 
KLF4-mCpG direct targets.
UGDH correlates with KLF4 expression in GBMs and is regulated by KLF4 via a DNA 
methylation-dependent mechanism
Next, we decided to perform detailed analysis on a single candidate to elucidate the 
mechanism underlying KLF4’s methylation dependent increase in GBM cell migration. We 
queried the REMBRANT database to assess gene expression in tumor and non-tumor 
specimens, and to determine whether selected genes correlate with KLF4 expression and 
patient survival in GBM. We chose UGDH as the model target because it was one of the 
three targets to have associations with GBM tumor progression. It is the least studied target 
in glioblastoma biology, and importantly, the only one to have consistent results across three 
cell lines we examined. We therefore focused on determining the biological function of 
UGDH in GBM as it is an important enzyme for the synthesis of extracellular matrix 
components. As shown in Figure 3A, UGDH was found to be upregulated in GBM samples 
when compared with normal brains. UGDH expression also moderately correlated with 
KLF4 expression in mesenchymal GBM samples (R= 0.32, P<0.001) (Figure 3B). 
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Furthermore, we found that high expression of UGDH is associated with poor survival in 
mesenchymal GBM patients (Figure 3C, P<0.05, UGDH high n=38, median survival =10.4 
months; UGDH low n=118, median survival =13.9 months).
With evidence supporting UGDH was upregulated by KLF4 WT only, but not the KLF4 
R458A, we determined whether UGDH expression is activated by KLF4 via a methylation-
dependent mechanism. We tested the effect of 5-aza-2′-deoxycytidine (5-Aza), a potent 
inhibitor of DNA methyltransferase, on KLF4 binding to the UGDH cis-regulatory region, 
and on UGDH expression. Cells treated with 5-Aza (1μmol/L) for 2 weeks had 80% fewer 
methylated sites in UGDH cis-regulatory regions (Figure 3D). Consistent with the reduction 
of mCpG sites, we observed a complete loss of KLF4 WT binding to the UGDH cis-
regulatory region in the presence of 5-Aza (Figure 3E). Furthermore, 5-Aza abrogated KLF4 
WT-induced UGDH upregulation by nearly 60% at both the mRNA and protein levels 
(Figure 3F, G). These results demonstrate in part that KLF4 activates UGDH transcription in 
a DNA methylation-dependent manner.
UGDH knockdown decreases GAG abundance and cell migration
Given the importance of extracellular matrix on GBM progression and the relatively 
unknown functional significance of UGDH in GBM, we focused our efforts on determining 
the biological function of UGDH in GBM cells. We hypothesized that knocking down 
UGDH would inhibit tumor cell migration and proliferation, because UGDH catalyzes the 
reaction that generates the key precursor for glycosaminoglycans, building blocks for 
extracellular matrix components.11 Two GBM model systems, U87 cells and GBM 
neurosphere cells HSR-GBM1A (GBM1A), were used to conduct UGDH loss-of-function 
studies. Each cell line was transduced with lentivirus containing either one of the two 
distinct UGDH shRNAs (sh#1, sh#2). Both shRNAs induced a significant reduction 
(80%-85%) in UGDH protein in U87 (Figure 4A, left panel) and GBM1A cells (Figure 4A, 
right panel). We tested the level of the end products of UGDH, GAGs, by utilizing a 
polysaccharide binding dye 1,9 dimethyl-methylene blue (DMMB). There was a substantial 
reduction in the abundance of cell-associated GAGs in UGDH knockdown cells when 
compared to cells transduced with control shRNAs (e.g., 48% by sh#1, P<0.001; and 79% 
by sh#2 in U87 cells, P<0.001) (Figure 4B; left panel). Similar effects were observed in 
GBM 1A cells (Figure 4B; right panel). To examine the effect of UGDH knockdown on 
GBM cell migration, transwell and wound healing scratch migration assays were performed 
in 0.1% serum medium to minimize cell proliferation. Transwell assays 24 hrs after cell 
plating revealed that UGDH silencing significantly decreased the migratory ability of GBM 
cells (by ~50% in U87, P<0.01, and 30% in GBM1A cells, P<0.05) (Figure 4C and 
Supplemental Fig. 2A). UGDH knockdown also decreased cell motility in wound healing 
assays by 25% (P<0.05) when compared to cells transduced with control shRNAs after 24 
hrs of scratch, and by 28% after 48 hrs (P<0.05) (Figure 4D and Supplemental Fig. 2B). 
Supplementing the culture medium with one of the GAGs, hyaluronic acid (HA, 100 ng/ml) 
rescued migration inhibition by UGDH shRNAs (Figure 4E), supporting the hypothesis that 
the effect of silencing UGDH on cell migration response is GAG-dependent. To substantiate 
the notion that the decreased cell migration in UGDH knockdown cells was not due to 
reduced cell growth under the given conditions and time points, we quantified the total cell 
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number at 48 hrs under 0.1% FBS, and did not find any significant difference in cell growth 
(115,000 ± 3000 vs 113,000 ±2000 and Supplemental Fig. 3A).
UGDH knockdown decreases GBM cell proliferation and clonogenicity
Studies show that, in addition to a prominent role in migration and metastasis, GAGs can 
influence signal transduction, proliferation and differentiation.10 We hypothesized that 
reduction of UGDH could also influence cell proliferation. Cell counting demonstrated that 
UGDH knockdown inhibited cell proliferation by 45% and 20-50% after 9 days in U87 and 
GBM1A cultures, respectively (Figure 5A, P<0.001). Trypan blue staining demonstrated the 
reduced cell growth was not due to cell death as both control cells and UGDH knockdown 
cells had comparable percentage of non-viable cells (Supplemental Fig. 3B). Next, we 
examined the effects of UGDH knockdown on clonogenicity of U87 cells and the capacity 
for neurosphere formation in GBM1A cells. We found that compared to controls, reduction 
of UGDH dramatically impaired the ability of U87 cells to form colonies in soft agar (by 
50-60%, P<0.001) (Figure 5B; left panel). We also observed a ~70% reduction in the 
neurosphere forming capacity of GBM neurosphere cells as compared with the controls 
(P<0.001) Figure 5B; right panel). Next, we analyzed cell cycle progression in U87 control 
and UGDH knockdown cells. Cell cycle was synchronized by incubating cells in 0.1% 
serum for 48 hrs, followed by stimulation with 10% serum for up to 32 hrs. Cell cycle 
progression was analyzed at 0, 8, 16, 24 and 32 hr post serum addition. At 0 h, both control 
and UGDH knockdown cells had ~80% of cells in G1/G0 phase. After replenishing serum 
for 32 hrs, 83% of UGDH knock down cells remained in G1/G0, in comparison to only 60% 
in control cells (P<0.001, Figure 5C, Supplementary Figure 4A). Thus, UGDH knockdown 
displayed a delay in G1/G0 to S phase transition. Analysis of cell cycle regulators by 
Western blot revealed a 65%-80% reduction in cyclin E and a 40-50% decrease in cyclin D1 
in UGDH knockdown cells (Figure 5D), providing further evidence that UGDH loss-of-
function promoted a delay in cell cycle progression, which led to decreased cell proliferation 
in GBM cells. Because UGDH is a rate limiting enzyme of producing GAGs, which can 
function as signaling molecules as well as a growth factor depot, we hypothesized that the 
decrease in proliferation of UGDH knockdown cells will be as a result of decrease in GAGs. 
To test this hypothesis, we performed rescuing experiments by adding HA (75ug/ml) to the 
UGDH knockdown cells and allowed them to grow for 9 days. We observed a significant 
rescue in the growth of UGDH knockdown cells on days 6 and 9 (Figure 5E). Furthermore, 
we surveyed a number of growth factor mediated signaling pathways. As shown in Figure 
5F, phosphorylated AKT (p-AKT) levels were dramatically downregulated in UGDH 
knockdown cells compared with that in non-silencing control cells. Total AKT (t-AKT) 
levels were slightly upregulated in UGDH knockdown cells. The ratio of p-AKT versus t-
AKT in UGDH knockdown cells were only 3-17% of that in non-silencing cells. This was 
consistent with our previously identified decrease in cyclin E1/D1, and a dramatic decrease 
in cell growth of UGDH knockdown cells.
UGDH knockdown reduces growth of GBM xenografts
The results that UGDH knockdown dramatically decreased GBM cell growth and migration 
in vitro prompted us to hypothesize that dramatic reduction of GAGs by UGDH knockdown 
would alter tumor growth in vivo. To examine the effect of UGDH silencing on orthotropic 
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GBM growth, we employed GBM1A cells that form infiltrative orthotropic xenografts in 
immunodeficient (SCID) mice to examine the effect of UGDH silencing in vivo. GBM1A 
cells stably expressing either control shRNA or UGDH shRNA#1 were implanted into the 
brains of SCID mice and sacrificed 50 days after implantation according to our previous 
studies using this model.20 Coronal brain sections were stained for hematoxylin and eosin. 
Tumor size measurement demonstrated a ~65% reduction in tumor growth in mice 
implanted with UGDH shRNA transduced cells (~2.0 mm3) compared to control shRNA 
transduced cells (~6.0 mm3) (Figure 6A, P<0.001). The anti-tumor effects of UGDH 
inhibition could be explained in part by a ~25% inhibition of the tumor cell proliferation 
index measured by anti-Ki67 immunohistochemical staining (Figure 6B, P<0.001), and 
~25% inhibition of the vascular density index measured by anti-laminin staining, 
respectively (Figure 6C, P<0.001).
UGDH knockdown decreases expression of extracellular matrix proteins and decreased 
tumor cell migration in GBM xenografts
Given the evidence that UGDH knockdown inhibits GAG expression in vitro, we 
investigated the extracellular matrix components in UGDH knockdown xenografts, 
hypothesizing that GAG expression inhibited by UGDH knockdown would alter 
extracellular matrix formation and therefore impact tumor growth. Expression of brevican, a 
proteoglycan downstream of UGDH pathway and tenascin C, a glycoprotein that binds and 
connects proteoglycans in the ECM, was quantified by immunohistochemical staining of 
intracranial xenograft sections from control and UGDH knockdown tumor groups. Brevican 
and tenascin C staining was reduced by 40-50% in tumors harboring UGDH shRNA 
compared to control tumors as evidenced by Image J software quantification of staining 
intensity (Figure 6D, E, P<0.001). In vitro Western blot analysis of U87 and GBM1A cells 
further confirmed reduced brevican (50%) and tenascin C (~65%) expression in response to 
UGDH silencing (Figure 6F, P<0.001). These results demonstrate that UGDH knockdown 
decreases the expression of GAGs and other extracellular matrix components in vitro and in 
vivo.
To determine the effect of UGDH knockdown on tumor cell migration in animals, we 
employed the internally-controlled dual-fluorescence approach developed in our laboratory.
23
 Since the size of UGDH knockdown xenografts was only 1/3 of that of control, to 
accommodate the discrepancy of tumor cell proliferation rate that may complicate the 
interpretation of tumor cell migration, we mixed 50,000 RFP-labeled control non-silencing 
tumor cells with 150,000 GFP-labeled UGDH knockdown cells, and injected the mixture 
into the mouse brains (n=3). In all three animals, the dual-fluorescence approach clearly 
demonstrated that even with 3 fold more injected numbers, UGDH knockdown cells were 
less migratory in vivo, consistent with our in vitro studies. An example of the results was 
shown in Figure 6G. The core of the tumor was stained with DAPI and showed in 
Supplemental Fig. 5.
UGDH is required for induction of GBM cell migration by KLF4-mCpG interactions
Finally, we investigated the involvement of UGDH in cellular phenotype changes induced by 
KLF4-mCpG interactions. In tet-on U87 and GBM1A KLF4 WT cells, we knocked down 
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UGDH expression with shRNAs to generate stable cells lines. Immunoblot analysis showed 
an ~80% to ~90% inhibition of UGDH in both U87 KLF4 WT and GBM1A KLF4 WT 
model systems (Figure 7A). KLF4 expression increased UGDH protein expression in the 
control shRNA transduced U87 and GBM1A cells as we have shown before, but failed to do 
so in the UGDH knockdown cell models (Figure 7A). A concomitant ~40-60% increase in 
GAGs in both U87 and GBM 1A cells was also observed after KLF4 WT expression was 
induced. However, UGDH knockdown abolished the increased GAG levels induced by 
KLF4 (Figure 7B). Next, we examined the effects of UGDH knockdown on KLF4-mCpG 
mediated GBM cell migration. KLF4 WT expression increased cell migration in transwell 
and wound healing assays, while UGDH knockdown reversed these changes induced by 
KLF4-mCpG interactions (Figure 7C, D). These results support that UGDH is required for 
cell migration mediated via KLF4 binding to methylated CpGs.
Discussion
Elevated glycosaminoglycan (GAG), major components in tumor microenvironment, has 
been shown to regulate multiple oncogenic pathways including tumor growth, invasion and 
migration.4,6,13 Consistent with these findings, several studies have demonstrated that 
inhibiting GAG synthesis diminishes tumor growth and metastasis.12,13,25 In our prior study, 
we found that krÜppel-like factor 4 (KLF4) promotes GBM cell migration by binding to 
methylated DNA (mCpG) and activating gene expression. In this study, we investigated a 
subset of KLF4-mCpG direct targets and focused on UDP-glucose dehydrogenase (UGDH), 
given its importance as an enzyme involved in the synthesis of the precursors for GAGs. 
Although UGDH is implicated as a rate-limiting and essential step in GAG monosaccharide 
synthesis9–11 the biological function of this enzyme in GBMs has not been explored. We 
demonstrate that UGDH is regulated via a methylation-dependent pathway; UGDH regulates 
cell migration and proliferation in vitro; silencing UGDH decreases levels of GAGs and 
some key components of the extracellular matrix in vitro and in vivo, and results in 
inhibition of GBM growth. A model of UGDH’s regulation and implication in GBM biology 
is proposed in Figure 8.
Expression of proteoglycan brevican and glycoprotein tenascin C, both of which are 
overexpressed in primary brain tumors as well as in experimental models of glioma, have 
been implicated in GBM progression.21,25,26 In our study, cell migration and proliferation 
was rescued by exogenous HA in UGDH knockdown cells, supporting the notion that the 
biological function of UGDH occurs via GAG production. Although it is not surprising that 
silencing UGDH expression leads to decreased tumor progression, our work provides a 
direct link between GAGs and other extracellular matrix proteins including tenascin C, a 
glycoprotein with a short carbohydrate chain. Tenascin C is shown to be elevated in the 
extracellular matrix of malignant brain tumor models and mediates tumor progression.21 In 
our GBM models, we found that a reduction of GAGs facilitates decreased expression of 
tenascin C in vitro and in vivo, possibly via a post-translational mechanism. It has been 
reported that in human brains, the most abundant gel-like, long charge GAG, hyaluronic 
acid, serves as the backbone for the connection of other proteoglycans such as the brevican, 
which are further linked by tenascin C. It is conceivable that a decrease in 
glycosaminoglycan expression would disrupt the formation of these complex networks, 
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resulting in a decreased deposit of tenascin C. The exact mechanism through which 
silencing UGDH induces a decrease in tenascin C requires further detailed studies.
Whereas silencing UGDH dramatically decreased tumor cell migration and proliferation in 
vitro, our in vivo UGDH knockdown xenografts showed a dramatic decrease in tumor 
growth, mainly via decreased tumor cell proliferation. Unlike our previously published 
studies on tenascin C21 in which the tumor/normal brain interface demonstrated well-
demarcated borders in TNC knockdown orthotropic xenografts, our UGDH knockdown 
models did not support a role for UGDH knockdown in tumor cell infiltration in vivo. This 
could be due to a moderate decrease in extracellular matrix components, such as brevican 
and tenascin C, in UGDH knockdown xenografts, as opposed to a complete elimination of 
these components in TNC knock down xenografts.21
DNA methylation, mainly at the C5 of the CpG dinucleotides, is present throughout the 
genome and more than 70% of CpGs are methylated in GBM.27,28 In fact, DNA 
hypermethylation is among the most commonly investigated epigenetic alterations in GBMs.
28
 An increased understanding of how abnormal DNA methylation patterns contribute to 
transcription factor binding ultimately leads to downstream gene transcription is important 
for developing effective epigenetic-related therapies against GBM tumor progression. In this 
work, the anti-proliferative and pro-migratory role of UGDH were shown in vitro; a DNA 
methylation-dependent mechanism for UGDH regulation was identified, and modulation of 
GBM cell migration via KLF4-mCpG interactions was demonstrated. While little is known 
about the epigenetic regulation of UGDH expression, this study shows for the first time that 
KLF4 upregulates UGDH expression via a methylation-dependent manner and also 
increases GAGs in GBM cells. In our previous studies, KLF4 in U87 cells did not affect cell 
proliferation in vitro.7 Similarly, in GBM1A cells, KLF4 did not affect GBM1A neurosphere 
proliferation in vitro (data not shown). Therefore, although UGDH knockdown had a 
profound effect on GBM cell growth inhibition in vitro and in vivo, our current models were 
not suitable to test whether UGDH was involved in KLF4-mediated gliomagenesis and 
tumor growth. We do found that KLF4 affects GBM cell differentiation, which will be 
followed up in the future.
Finally, considering the importance of the enzyme UGDH in GAG synthesis and the critical 
role of GAG in tumor growth, we provide evidence supporting the notion that UGDH could 
be a potential therapeutic target to treat GBM malignancy. Future studies with small 
molecular inhibitors specific for UDGH would test if UGDH could serve as a therapeutic 
target alone or in combination with other therapies for GBMs.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Schematic illustration of GAG synthesis pathway, different GAGs and UGDH function in 
GAG synthesis.
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Figure 2. KLF4-mCpG binding activity activates genes involved in GBM cytoskeletal 
organization and migration
(A) Upper panel: Western blot analysis showed KLF4 WT or KLF4 R458A expression in 
tet-on stable U87 GBM cell lines upon doxycyline treatment (1 ug/ml, 48 hrs). Lower panel: 
Twenty putative KLF4-mCpG gene targets involved in cell migration pathway were picked 
from our previous RNA-seq studies. Real time-PCR (RT-PCR) revealed 11 of the 20 genes 
were significantly upregulated by KLF4 WT only, with no change in KLF4 R458A 
expressing cells (+Dox, 48 hr), confirming a mCpG-dependent gene activation mechanism 
(asterisks). Bold showed targets with methylated cis-regulatory elements in the gene. (B) 
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Sanger bisulfite sequencing indicated DNA methylation in tested cis-regulatory regions of 
putative KLF4-mCpG targets. Examples of four genes showed highly methylated KLF4 
binding regions of these genes. Each row represents one sequenced clone; each column 
represents one CpG site; filled circles stand for methylation. (C) Confirmation that KLF4 
WT but not KLF4 R458R preferentially bound to the methylated cis-regulatory regions of 
selected genes. A KLF4 antibody was used to precipitate cross-linked genomic DNA from 
U87 cells expressing KLF4 WT or KLF4 R458A. Rabbit IgG was used to control for non-
specific binding. De-crosslinked DNA samples were served as the input for ChIP-PCR. 
KLF4 binding to the selected regions was enriched in KLF4 WT expressing cells. (D) 
Western blot analysis indicating increased protein expression of the selected targets by 
KLF4 WT, but not by KLF4 R458A.
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Figure 3. UDGH correlates with KLF4 expression in GBM samples and is regulated via a mCpG 
dependent mechanism by KLF4
(A) UGDH gene expression intensity (mean) from REMBRANDT database. UGDH 
expression is significantly upregulated in GBM samples when compared with non-neoplastic 
brain samples (P<0.001). (B) Pearson’s correlation plots of UGDH and KLF4 expression in 
mesenchymal glioma patients of mesenchymal subtype. Plots show positive correlation in 
the expression of UGDH and KLF4 (R=0.32, P < 0.001). (C) Kaplan-Meier Survival Plots 
for mesenchymal glioma patients based on differential gene expression of UGDH (from 
REMBRANT database). The probability of survival is significantly lower in samples with 
high UGDH gene expression compared to samples with low expression in GBM 
mesenchymal subtype (P < 0.001). (D) Upper panel: schematic of UGDH gene structure 
showing KLF4 binding site on the first intron. Lower panels: sanger bisulfite sequencing of 
DNA methylation on KLF4 binding site of UGDH gene before and after treatment with 
DNA methyltransferase inhibitor 5-Aza. Cells pretreated with 5-aza showed 80% reduction 
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in DNA methylation. (E) ChIP-PCR showed KLF4 WT preferentially bound to the 
methylated cis-regulatory region of UGDH; 5-aza treatment decreased KLF4 WT binding to 
UGDH. (F) RT-PCR showed UGDH mRNA was significantly induced by KLF4 WT only, 
which was abrogated by 5-aza. (G) Western blot showed induction of UGDH by KLF4 WT 
only. Consistent with ChIP-PCR and RT-PCR, 5-aza treatment partially blocked UGDH 
induction by KLF4 WT, in keeping with a methylation-dependent mechanism.
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Figure 4. UGDH knockdown decreases GAG abundance and cell migration
(A) U87 and HSR-GBM1A (GBM1A) cells were transduced with lentivirus coding for 
nonsilencing shRNA (Control), UGDH shRNA #1 or UGDH shRNA #2. UGDH knockdown 
was quantified by immunoblot analysis. Both UGDH shRNAs decreased UGDH protein 
level by more than 80%. (B) Sulfated GAG (sGAG) concentration was quantified by DMMB 
assay. UGDH knockdown showed significant reduction in GAG concentration in both U87 
(Left panel) and GBM1A cells (right panel). (C) Transwell migration assays showed 
significant decrease in migration of UGDH knockdown U87 cells (left panel) and GBM1A 
cells (right panel). (D) Wound healing scratch assays showed UGDH knockdown decreased 
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migration in U87 cells. (E). Exogenous HA rescued cell migration in scratch assays, in both 
U87 control and UGDH shRNA transduced cells.
Oyinlade et al. Page 21





















Figure 5. UGDH Knockdown decreases GBM cell proliferation and clonogenicity
(A) Cell growth curve up to 9 days after plating. Trypsinized cells were stained with Trypan 
blue and both viable (unlabeled) cells were counted on the days indicated. (B) Colony 
formation assays showing significant decrease in anchorage independent clongenicity in 
UGDH knockdown U87 cells (right panel). For GBM neurosphere cells, equal numbers of 
viable GBM1A cells were plated and cultured for 14 days to allow neurosphere formation. 
Neurospheres (>100 μm diameter) were counted with MCID software. UGDH silencing 
inhibited neurosphere formation. (C) Cell cycle was synchronized. There was a delayed 
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progression to S phase in U87 UGDH knockdown cells compared to controls after 32 hrs of 
serum replenishing. (D) UGDH silencing decreased cyclin D1 and E protein levels in GBM 
cells. (E). HA (75ug/ml) supplemented in U87 cells rescued the decreased cell growth effect 
observed in UGDH knockdown cells on days 6 and 9. (F) Phosphorylated AKT levels were 
significantly decreased in UGDH knockdown U87 cells compared to controls as evidenced 
by Western blots (*: P < 0.05; ** P<0.01; *** P<0.001).
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Figure 6. UGDH knockdown inhibits GBM growth and migration in vivo
(A) Control shRNA or UGDH shRNA transduced GBM1A cells (100,000) were implanted 
by stereotactic injection to caudate/putamen of severe combined immunodeficiency mice 
(SCID). Animals were sacrificed 50 days after implantation. Hematoxylin and eosin-stained 
coronal brain sections (20 μm) obtained from animals showed dramatically decreased tumor 
size in UGDH knockdown groups (left panels, bar = 500 μm). Right panel: quantification of 
xenograft tumor volume shows that silencing UGDH repressed xenograft growth by more 
than 65% (6.4 in control vs. 2.3 in UGDH sh#1, P < 0.001). B. UGDH knockdown 
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significantly inhibited tumor cell proliferation by 31% as evidenced by Ki67 staining. C. 
UGDH loss-of-function inhibited blood vessel density by 25% as evidenced by laminin 
staining. (D, E) Xenografts with UGDH knockdown decreased the abundance of key 
extracellular matrix components tenascin C and brevican in GBM1A xenografts. B to E: Bar 
= 20 μm. (F) Western blots showing decreased brevican and tenascin C protein in U87 
UGDH knockdown cells in vitro. (G). A mixture of RFP-labeled control non-silencing cells 
(50,000) and GFP-labeled UGDH knockdown cells (150,000) was injected into the mouse 
brain. Dual-fluorescence experiment showed that UGDH knockdown cells (green) stayed in 
the tumor core (arrowheads), whereas the control cells (red) were preferentially located in 
the tumor periphery (arrows). Bar = 200 μm.
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Figure 7. UGDH is required for KLF4-mCpG-dependent increase in GBM cell migration
(A) U87 KLF4 WT and GBM1A KLF4 WT cells were transduced with lentivirus coding for 
nonsilencing shRNA (Control), UGDH shRNA #1 or UGDH shRNA #2. Cells were treated 
with Dox for 48 hrs before each analysis. Western blot showed UGDH knockdown 
significantly reverses KLF4 WT dependent induction of UGDH in both U87 and GBM1A 
cells. (B) Sulfated GAG (sGAG) concentration in U87 and GBM1A cells expressing KLF4 
WT was determined by DMMB assay. UGDH knockdown significantly decreased the KLF4 
dependent increase in GAG concentration (C) UGDH knockdown significantly reversed the 
KLF4-dependent increase in cell migration in transwell assays. Cell migration was evaluated 
24 hrs later by counting DAPI-stained cells. Five fields per well were counted. (D) U87 
KLF4 WT cells harboring UGDH shRNA were treated with Dox for 5 days till confluence. 
A scratch was made and cells were maintained in 0.1% FCS medium overnight. 
Microphotographs were taken 0 hr and 24 hrs after scratching. Bar = 100 um. UGDH 
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knockdown inhibited the increased ability of KLF4 WT cells to migrate towards scratched 
area.
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A model of UGDH’s regulation and implication in GBM biology.
Oyinlade et al. Page 28
Oncogene. Author manuscript; available in PMC 2018 August 26.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
